Financials
| 1st Quarter Results | Apr. 29, 2026 |
| Filing of Form 20-F with SEC | Feb. 25, 2026 |
| Annual Financial Report | Feb. 24, 2026 |
| Final Results | Feb. 10, 2026 |
| H1 and Q2 2025 results | Jul. 29, 2025 |
| 1st Quarter Results | Apr. 29, 2025 |
| Annual Financial Report | Feb. 18, 2025 |
Proxies
| Result of AGM | Apr. 09, 2026 |
| Notice of AGM | Mar. 10, 2026 |
| Form of Proxy | Sep. 29, 2025 |
| Result of AGM | Apr. 11, 2025 |
| Special Business Approved at AGM | Apr. 12, 2024 |
| Proxy Form for 2024 AGM | Mar. 07, 2024 |
| Notice of AGM | Mar. 07, 2024 |
Ownership Update
| Director/PDMR Shareholding | Mar. 06, 2026 |
| Director/PDMR Shareholding | Mar. 06, 2026 |
| Director/PDMR Shareholding | Mar. 06, 2026 |
| Director/PDMR Shareholding | Dec. 22, 2025 |
| Director/PDMR Shareholding | Dec. 19, 2025 |
| Director/PDMR Shareholding | Nov. 14, 2025 |
| Director/PDMR Shareholding | Nov. 10, 2025 |
Announcements
| Total Voting Rights and Admission of Shares | May. 01, 2026 |
| FDA ODAC vote on camizestrant in breast cancer | May. 01, 2026 |
| FDA ODAC recommends Truqap in prostate cancer | May. 01, 2026 |
| Breztri approved in the US for asthma | Apr. 28, 2026 |
| Saphnelo self-administration approved in the US | Apr. 27, 2026 |
| Directorate change | Apr. 23, 2026 |
| I CAN PhIII interim analysis met primary endpoint | Apr. 21, 2026 |
Prospectuses
| AstraZeneca prices a $2bn bond offering | Feb. 26, 2026 |
| AstraZeneca prices a €1.4bn bond offering | Jul. 30, 2024 |
| AstraZeneca prices a $5bn bond offering | Feb. 22, 2024 |
| AstraZeneca prices a $2.25bn bond offering | Mar. 01, 2023 |
| AstraZeneca PLC;AstraZeneca Finance LLC - Base prospectus (debt) | Jun. 15, 2022 |
| AstraZeneca prices a EUR800m bond offering | May. 27, 2021 |
| AstraZeneca prices a $7bn bond offering | May. 26, 2021 |